Why the study?
Heart failure is an increasing global health problem with profound sex-related differences in cause, treatment, and prognosis.
Does achieving optimal medical treatment reduce 5-point MACE in patients with HFrEF?
Does achieving optimal medical treatment reduce 5-point MACE in patients with HFrEF?
Achieving optimal medical therapy (≥50% target dose of RAS inhibitor and beta-blocker) is associated with reduced 5-point MACE in HFrEF patients, though it is more frequently achieved in men.
Sex disparities in OMT achievement may warrant targeted clinic interventions; leaves open whether equitable GDMT improves prognosis.
BACKGROUND: Heart failure (HF) is an increasing health problem globally. Profound sex-related differences have been observed regarding the cause, treatment, and prognosis of HF. AIM: To assess baseline predictors for achieving optimal medical treatment (OMT) and the prognostic importance of OMT for male and female patients who have attended a HF clinical program (HFCP). METHODS: OPTIHEART was a retrospective study that included 870 consecutive patients with left ventricular ejection fraction (LVEF)≤40% discharged from HFCP in 2018, 2019 or 2020 and followed in registers for a mean of 1083(SD 11.3) days. OMT was defined as receiving an angiotensin-converting-enzyme-inhibitor (ACEi), angiotensin-receptor blocker (ARB) or angiotensin-II-receptor blocker and nephrylisin-inhibitor (ARNI) AND a betablocker (BB) both in doses ≥ 50% of target doses. RESULTS: . CONCLUSION: OMT was more frequently achieved in patients with male sex independently of age, DBP, and creatinine. Achieving OMT was associated with less 5-point MACE independently of female sex, younger age, never smoking and NYHA ≤ 2.
No takes yet. Share an insight, caveat, or question.
Sharfo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: